These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 33773605

  • 41. Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012.
    Marinho-Dias J, Lobo J, Henrique R, Baldaque I, Pinho-Vaz C, Regadas L, Branca R, Campilho F, Campos A, Medeiros R, Sousa H.
    Mol Med Rep; 2018 Nov; 18(5):4650-4656. PubMed ID: 30221663
    [Abstract] [Full Text] [Related]

  • 42. Non-uniform in vivo Expansion of Epstein-Barr Virus-Specific T-Cells Following Donor Lymphocyte Infusion for Post-transplant Lymphoproliferative Disease.
    Burns DM, Ryan GB, Harvey CM, Nagy E, Hughes S, Murray PG, Russell NH, Fox CP, Long HM.
    Front Immunol; 2019 Nov; 10():2489. PubMed ID: 31736946
    [Abstract] [Full Text] [Related]

  • 43. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients.
    San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P, ESCMID Study Group of Infection in Compromised Hosts.
    Clin Microbiol Infect; 2014 Sep; 20 Suppl 7():109-18. PubMed ID: 24475976
    [Abstract] [Full Text] [Related]

  • 44. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. [Gastrointestinal post-transplant lymphoproliferative disorder with rapidly forming characteristic lesions after cord blood transplantation: a report of two cases].
    Sato Y, Sumi M, Ueki T, Kaiume H, Kirihara T, Takeda W, Kurihara T, Sato K, Hiroshima Y, Tokutake K, Kimura T, Watanabe M, Kobayashi H.
    Rinsho Ketsueki; 2016 Oct; 57(12):2496-2501. PubMed ID: 28090016
    [Abstract] [Full Text] [Related]

  • 47. Aggressive Epstein-Barr virus-negative B-cell post-transplant lymphoproliferative disorder in a hepatitis C-negative liver transplant recipient who received a hepatitis C-positive graft: Implications for D+/R- hepatitis C virus seroconversion.
    Kutzler HL, Collins K, Maneckshana B, Rochon C, Einstein M, Mnayer L, Rezuke WN, Sheiner P, Serrano OK.
    Transpl Infect Dis; 2019 Oct; 21(5):e13144. PubMed ID: 31291501
    [Abstract] [Full Text] [Related]

  • 48. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice.
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, Guzman-Becerra N, Joshi M, Mehta A, Navarro WH, Nikiforow S, O'Reilly RJ, Reshef R, Ruiz F, Spindler T, Prockop S.
    Lancet Oncol; 2024 Mar; 25(3):376-387. PubMed ID: 38309282
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD, Durand KA, Solernou V, Bosaleh A, Balbarrey Z, García de Dávila MT, Rodríguez M, Irazu L, Alonio LV, Picconi MA.
    Rev Argent Microbiol; 2016 Mar; 48(2):110-8. PubMed ID: 27157146
    [Abstract] [Full Text] [Related]

  • 56. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
    Chiereghin A, Bertuzzi C, Piccirilli G, Gabrielli L, Squarzoni D, Turello G, Ferioli M, Sessa M, Bonifazi F, Zanoni L, Sabattini E, Lazzarotto T.
    Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
    [Abstract] [Full Text] [Related]

  • 57. EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.
    Law N, Logan C, Taplitz R.
    Viruses; 2024 Aug 14; 16(8):. PubMed ID: 39205268
    [Abstract] [Full Text] [Related]

  • 58. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
    Jiménez S.
    Clin J Oncol Nurs; 2015 Feb 14; 19(1):94-8. PubMed ID: 25689655
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder.
    Shimizu H, Saitoh T, Koya H, Yuzuriha A, Hoshino T, Hatsumi N, Takada S, Nagaki T, Nojima Y, Sakura T.
    Int J Hematol; 2011 Nov 14; 94(5):495-8. PubMed ID: 22038015
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.